CDXI Projected Dividend Yield
Cardax Inc ( OTCBB : CDXI )Cardax is a biopharmaceutical company focused on the development of pharmaceuticals to address one of the main underlying causes of various chronic diseases, inflammation. Co. also has a commercial business unit that markets dietary supplements for inflammatory health. CDX-101, Co.'s primary pharmaceutical candidate, is in pre-clinical development for cardiovascular inflammation and dyslipidemia, with a target initial indication of severe hypertriglyceridemia. CDX-301 is Co.'s pre-clinical stage pharmaceutical candidate for macular degeneration. ZanthoSyn® is a physician recommended astaxanthin dietary supplement for inflammatory health. 20 YEAR PERFORMANCE RESULTS |
CDXI Dividend History Detail CDXI Dividend News CDXI Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |